Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:DYAX
Previous Symbol
CUSIP26746E10
Phone+1-617-2505769
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Dyax (NASDAQ:DYAX) Frequently Asked Questions
What is Dyax's stock symbol?
Dyax trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax's earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) released its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.96 million. The business's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.01) earnings per share. View Dyax's Earnings History.
Has Dyax been receiving favorable news coverage?
Media stories about DYAX stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dyax earned a news impact score of 1.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Dyax?
Shares of DYAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyax's stock price today?
One share of DYAX stock can currently be purchased for approximately $38.41.
What is Dyax's official website?
How can I contact Dyax?
Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.
MarketBeat Community Rating for Dyax (NASDAQ DYAX)
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe DYAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
